ArticleFrontiers in oncology2026
Synchronous metastatic differentiated high-grade thyroid carcinoma in lymph node from classic papillary thyroid carcinoma: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Differentiated high-grade thyroid carcinoma (DHGTC) is relatively uncommon. This case report described a 61-year-old male initially diagnosed with classic papillary thyroid carcinoma confined to the thyroid gland, accompanied by skip metastasis to a Level II lymph node. The metastatic lymph node exhibited histopathological progression to DHGTC. Following thyroidectomy for the primary tumor and neck dissection for the metastatic lymph node, the patient received adjuvant radiotherapy to the neck. Subsequently, pathological examination confirmed multiple pulmonary metastases (PMs) from DHGTC within six months of the initial diagnosis. Unfortunately, a post-therapeutic ¹³¹I scan revealed no uptake in the PMs. Genetic testing of the PMs revealed no mutations in BRAF, KRAS, or NRAS, and no RET rearrangement. The patient's condition was subsequently managed with targeted therapy and immunotherapy, which achieved disease stabilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.